Prostatic Acid Phosphatase
Synonyms |
|
||||||||
Cerner Name |
|||||||||
Clinical Info |
An adjunct in the evaluation of possible prostatic malignancy and useful in monitoring therapeutic progress |
||||||||
Specimen Sources |
Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous |
||||||||
Specimen Types |
Blood |
||||||||
Container |
Red Top Tube |
||||||||
Collection Instructions |
Container/Tube: Gold Top Tube |
||||||||
Specimen Volume |
0.5 mL serum (0.3 mL min) |
||||||||
Transport Instructions |
Refrigerated |
||||||||
Specimen Stability |
3 Hours Room Temperature |
||||||||
Methodology |
Immunochemiluminometric assay (ICMA) |
||||||||
Days Performed |
TAT: 3-4 Days |
||||||||
Performing Laboratory |
LabCorp |
||||||||
CPT |
84066 |
||||||||
PDM |
5900130 |
||||||||
Only Orderable at Locations: |
Orderable Everywhere |
||||||||
Results |
|
||||||||
Result Interpretation0−3.5 ng/mL
Prostatic acid phosphatase has been used as a tumor marker ever since the observation by Gutman in 19381 that elevated levels of this enzyme are found in patients with metastatic prostate cancer. PAP determination in conjunction with PSA measurements is useful in assessing the prognosis of prostate cancer.2 Measurement of two markers allows identification of prostate cancer patients who have an elevation of PAP but not of PSA, and thus help monitoring the course of disease and response to treatment. PAP is more specific than PSA and less false-positives are seen due to benign prostatic hyperplasia. |
|||||||||
Forms |